Podcast episode 46 (in German)
Thymalin: the immune bioregulator fact-checked
August 17, 2026
The thymus, the training ground of the T cells, shrinks from puberty onwards and has almost disappeared by 70. Thymalin is supposed to give the aging immune system a boost and has the most striking mortality data in the peptide world, all from a single school of research.
What it is about
Thymalin is a polypeptide extract from calf thymus and has been approved as a medicine in the Soviet Union and Russia since 1982, originally for immune recovery after radiation exposure. It was developed by the military physician Vladimir Khavinson, who pursued the idea of organ-specific short peptides, the so-called bioregulators, for 40 years. The episode explains the involution of the thymus, the aging of the immune system and inflammaging, describes the effect on T cells and gene activity and presents the long-term mortality data. At the end stands a preparation that addresses a real, underestimated driver of aging, with impressive figures that have not yet been independently replicated.
Key points
- Vladimir Khavinson, 1946 to 2024, headed the Institute of Bioregulation and Gerontology in Saint Petersburg and published more than 700 papers.
- The active core of Thymalin consists mainly of peptides made of 2 amino acids, such as glutamyl-tryptophan; Thymogen is a fully synthetic version of it.
- According to Khavinson’s data, Thymalin normalizes the ratio of helper to suppressor T cells and increases antibody production and phagocyte activity; inflammation markers also fell.
- In long-term studies by the Khavinson group, summarized among others in 2003 in Neuroendocrinology Letters, older people receiving courses of Thymalin over 6 to 8 years had about 2-fold lower mortality than untreated controls.
- In the group that combined Thymalin with the pineal bioregulator Epithalamin, mortality was around 4-fold lower, along with fewer respiratory infections and better cardiovascular values.
- In the Russian clinical literature from 4 decades, Thymalin is considered well tolerated; mainly injection-site reactions are reported, rarely allergic ones.
- The Khavinson school also offers oral short-peptide capsules whose peptides of 2 to 3 amino acids are said to partly survive digestion; the data are thinner than for the injection.
Where the data stop
The mortality data come almost entirely from one research group and from Russian journals, with a methodology that does not meet Western approval standards: no large double-blind, independently replicated studies. That does not make the figures wrong, but proof by Western standards is lacking, and how much weight to give them remains a judgment call.
In the EU, Thymalin is not approved, as of August 2026; outside Russia it is a research product, and with an organ extract everything depends on manufacturing quality. Anyone with an autoimmune disease or an organ transplant does not take an immune stimulant without medical supervision; there are no data for pregnant women. For the thymus without a peptide, there remain zinc, exercise, protein, sleep and little chronic stress.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on August 17, 2026.
The topic in the database
- The flagship of the Khavinson school: a thymus peptide complex against immune aging – with the most astonishing long-term mortality data in the …Thymalin
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-26.